Trenbolone cyclohexylmethylcarbonate

Trenbolone cyclohexylmethylcarbonate (also known as Parabolan) is a potent anabolic steroid developed for veterinary use. It is a derivative of nandrolone, but unlike nandrolone, it has a strong binding affinity to the androgen receptor, making it one of the strongest injectable anabolic steroids.

History

Trenbolone cyclohexylmethylcarbonate was first developed in the late 1960s by Negma Laboratories, a French pharmaceutical company. It was marketed under the brand name Parabolan and was used for a short period in the human medical field. However, it was discontinued in the late 1990s and is no longer manufactured.

Pharmacology

Trenbolone cyclohexylmethylcarbonate is a prodrug of trenbolone. It is metabolized in the body to release trenbolone, which then interacts with the androgen receptor. This interaction leads to an increase in protein synthesis and nitrogen retention, resulting in significant muscle growth and strength gains.

Side Effects

Like all anabolic steroids, trenbolone cyclohexylmethylcarbonate has potential side effects. These include androgenic effects such as acne and hair loss, as well as cardiovascular effects such as high blood pressure and increased heart rate. It can also have negative effects on the endocrine system, including suppression of natural testosterone production.

Legal Status

In many countries, including the United States, trenbolone cyclohexylmethylcarbonate is classified as a controlled substance. It is illegal to possess or distribute without a prescription. In the world of sports, it is banned by most major athletic organizations due to its performance-enhancing effects.

See Also

• Anabolic steroid
• Androgen receptor
• Nandrolone
• Prodrug

This article is a stub related to pharmacology. You can help WikiMD by expanding it!